Avid has installed the appropriate systems to allow integration of the Mobius bioreactors. The 40,000-square foot Myford facility was designed to accommodate a fully disposable biomanufacturing process for late Phase III clinical and commercial biologics production. The facility can operate multiple bioreactors simultaneously, improving manufacturing capacity and efficiency.
“An integral part of our complete single-use offering, Mobius® bioreactors help companies like Avid move toward the goal of fully disposable manufacturing,” said Udit Batra, member of the Executive Board, Merck KGaA, Darmstadt, Germany and chief executive officer, MilliporeSigma. “We will continue to support Avid as it upgrades its facility to help customers advance molecules into the clinic and to market so that patients have better access to life-enhancing drugs.”
“We ran a competitive process and chose the MilliporeSigma Mobius 2,000-liter single-use bioreactor system because it offers technical and ease of use advantages over competing single-use systems,” said Steven W. King, president, Avid Bioservices. “The confidence in the choice has only been further reinforced by our experience to date with the Mobius® system up to the 1000-liter scale as part of a pilot program. Adding the Mobius®technology to expand Avid’s Myford biomanufacturing capacity highlights our commitment to offer customers the latest single-use equipment and flexible solutions.” King added that the first 2,000-liter pilot batch is planned for later this month.
